Tyler P. Graf
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tyler P. Graf has a total of 148 co-authors. Here are the top co-authors by number of shared publications:
- Kevin J. McHugh
Rice University
10 shared publications - Erin M. Euliano
Department of Bioengineering, Rice University
5 shared publications - Ana Jaklenec
David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, USA
4 shared publications - Marina H. Yu
Department of Bioengineering, Rice University, Houston, USA
4 shared publications - Robert Langer
David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, USA
4 shared publications Alyssa A. Kunkel
Department of Bioengineering Rice University 6100 Main St Houston TX 77005 USA
3 shared publications
Latest Publications
- 3 April 2026
- Published by Taylor & Francis in Future Virology
- Vol. 21 (4) , 275-288
Working toward a single-dose vaccine for rabies post-exposure prophylaxis
Rabies is almost universally fatal if not treated before symptoms appear. Fortunately, post-exposure prophylaxis (PEP) is a nearly 100% effective treatment when started soon after rabies exposure. Nevertheless, rabies causes approximately 59,000 deaths annually, predominantly in rural parts of low- and middle-income countries. Current World Health Organization rabies PEP protocols require 1) a single administration of rabies immunoglobulin and 2) three or four doses of a vaccine administered over one to two weeks. The need for multiple healthcare visits significantly reduces treatment adherence due to financial, geographic, and other logistical barriers. Single-dose vaccine strategies represent a potential avenue to overcome these limitations by consolidating the vaccine dosing regimen into a single clinical interaction with a healthcare professional. This narrative review highlights several of the most promising technologies being used to pursue this goal, including mRNA vaccines, controlled-release formulations, and microneedle delivery systems. Although these strategies have yet to achieve clinical success in humans, data generated in preclinical studies and clinical trials offer insight into the limitations and potential benefits of these approaches as the field continues to seek a single-dose vaccine for PEP treatment. Highlighted articles were found by searching PubMed and Google Scholar, and published between January 2015 and August 2025.
- 3 April 2026
- Published by Taylor & Francis in Future Virology
- Vol. 21 (4) , 275-288
Working toward a single-dose vaccine for rabies post-exposure prophylaxis
Rabies is almost universally fatal if not treated before symptoms appear. Fortunately, post-exposure prophylaxis (PEP) is a nearly 100% effective treatment when started soon after rabies exposure. Nevertheless, rabies causes approximately 59,000 deaths annually, predominantly in rural parts of low- and middle-income countries. Current World Health Organization rabies PEP protocols require 1) a single administration of rabies immunoglobulin and 2) three or four doses of a vaccine administered over one to two weeks. The need for multiple healthcare visits significantly reduces treatment adherence due to financial, geographic, and other logistical barriers. Single-dose vaccine strategies represent a potential avenue to overcome these limitations by consolidating the vaccine dosing regimen into a single clinical interaction with a healthcare professional. This narrative review highlights several of the most promising technologies being used to pursue this goal, including mRNA vaccines, controlled-release formulations, and microneedle delivery systems. Although these strategies have yet to achieve clinical success in humans, data generated in preclinical studies and clinical trials offer insight into the limitations and potential benefits of these approaches as the field continues to seek a single-dose vaccine for PEP treatment. Highlighted articles were found by searching PubMed and Google Scholar, and published between January 2015 and August 2025.
- 25 October 2024
- Published by Wiley in Advanced Healthcare Materials
- Vol. 14 (3) , e2402958
A TLR7 Agonist Conjugated to a Nanofibrous Peptide Hydrogel as a Potent Vaccine Adjuvant
Toll‐like receptors (TLRs) recognize pathogen‐ and damage‐associated molecular patterns and, in turn, trigger the release of cytokines and other immunostimulatory molecules. As a result, TLR agonists are increasingly being investigated as vaccine adjuvants. Many of these agonists are small molecules that quickly diffuse away from the vaccination site, limiting their co‐localization with antigens and, thus, their effect. Here, the small‐molecule TLR7 agonist 1V209 is conjugated to a positively‐charged multidomain peptide (MDP) hydrogel, K2, which was previously shown to act as an adjuvant promoting humoral immunity. Mixing the 1V209‐conjugated K2 50:50 with the unfunctionalized K2 produces hydrogels that retain the shear‐thinning and self‐healing physical properties of the original MDP while improving the solubility of 1V209 more than 200‐fold compared to the unconjugated molecule. When co‐delivered with ovalbumin as a model antigen, 1V209‐functionalized K2 produces a robust Th2 immune response and an antigen‐specific Th1 immune response superior to alum, a widely used vaccine adjuvant. Together, these results suggest that K2 MDP hydrogels functionalized with 1V209 are a promising adjuvant for vaccines against infectious diseases, especially those benefiting from a combined Th1 and Th2 immune response.
- 25 October 2024
- Published by Wiley in Advanced Healthcare Materials
- Vol. 14 (3) , e2402958
A TLR7 Agonist Conjugated to a Nanofibrous Peptide Hydrogel as a Potent Vaccine Adjuvant
Toll‐like receptors (TLRs) recognize pathogen‐ and damage‐associated molecular patterns and, in turn, trigger the release of cytokines and other immunostimulatory molecules. As a result, TLR agonists are increasingly being investigated as vaccine adjuvants. Many of these agonists are small molecules that quickly diffuse away from the vaccination site, limiting their co‐localization with antigens and, thus, their effect. Here, the small‐molecule TLR7 agonist 1V209 is conjugated to a positively‐charged multidomain peptide (MDP) hydrogel, K2, which was previously shown to act as an adjuvant promoting humoral immunity. Mixing the 1V209‐conjugated K2 50:50 with the unfunctionalized K2 produces hydrogels that retain the shear‐thinning and self‐healing physical properties of the original MDP while improving the solubility of 1V209 more than 200‐fold compared to the unconjugated molecule. When co‐delivered with ovalbumin as a model antigen, 1V209‐functionalized K2 produces a robust Th2 immune response and an antigen‐specific Th1 immune response superior to alum, a widely used vaccine adjuvant. Together, these results suggest that K2 MDP hydrogels functionalized with 1V209 are a promising adjuvant for vaccines against infectious diseases, especially those benefiting from a combined Th1 and Th2 immune response.
- Open Access
- 17 July 2024
- Published by Wiley in Bioengineering & Translational Medicine
- Vol. 9 (6) , e10705
Intra‐lymph node crosslinking of antigen‐bearing polymers enhances humoral immunity and dendritic cell activation
Lymph node (LN)‐resident dendritic cells (DCs) are a promising target for vaccination given their professional antigen‐presenting capabilities and proximity to a high concentration of immune cells. Direct intra‐LN injection has been shown to greatly enhance the immune response to vaccine antigens compared to traditional intramuscular injection, but it is infeasible to implement clinically in a vaccination campaign context. Employing the passive lymphatic flow of antigens to target LNs has been shown to increase total antigen uptake by DCs more than inflammatory adjuvants, which recruit peripheral DCs. Herein, we describe a novel vaccination platform in which two complementary multi‐arm poly(ethylene glycol) (PEG) polymers—one covalently bound to the model antigen ovalbumin (OVA)—are injected subcutaneously into two distinct sites. These materials then drain to the same LN through different lymphatic vessels and, upon meeting in the LN, rapidly crosslink. This system improves OVA delivery to, and residence time within, the draining LN compared to all control groups. The crosslinking of the two PEG components also improves humoral immunity without the need for any pathogen‐mimicking adjuvants. Further, we observed a significant increase in non‐B/T lymphocytes in LNs cross‐presenting the OVA peptide SIINFEKL on MHC I over a dose‐matched control containing alum, the most common clinical adjuvant, as well as an increase in DC activation in the LN. These data suggest that this platform can be used to deliver antigens to LN‐resident immune cells to produce a stronger humoral and cellular immune response over materials‐matched controls without the use of traditional adjuvants.
- 17 July 2024
- Published by Wiley in Bioengineering & Translational Medicine
- Vol. 9 (6) , e10705
Open AccessIntra‐lymph node crosslinking of antigen‐bearing polymers enhances humoral immunity and dendritic cell activation
Lymph node (LN)‐resident dendritic cells (DCs) are a promising target for vaccination given their professional antigen‐presenting capabilities and proximity to a high concentration of immune cells. Direct intra‐LN injection has been shown to greatly enhance the immune response to vaccine antigens compared to traditional intramuscular injection, but it is infeasible to implement clinically in a vaccination campaign context. Employing the passive lymphatic flow of antigens to target LNs has been shown to increase total antigen uptake by DCs more than inflammatory adjuvants, which recruit peripheral DCs. Herein, we describe a novel vaccination platform in which two complementary multi‐arm poly(ethylene glycol) (PEG) polymers—one covalently bound to the model antigen ovalbumin (OVA)—are injected subcutaneously into two distinct sites. These materials then drain to the same LN through different lymphatic vessels and, upon meeting in the LN, rapidly crosslink. This system improves OVA delivery to, and residence time within, the draining LN compared to all control groups. The crosslinking of the two PEG components also improves humoral immunity without the need for any pathogen‐mimicking adjuvants. Further, we observed a significant increase in non‐B/T lymphocytes in LNs cross‐presenting the OVA peptide SIINFEKL on MHC I over a dose‐matched control containing alum, the most common clinical adjuvant, as well as an increase in DC activation in the LN. These data suggest that this platform can be used to deliver antigens to LN‐resident immune cells to produce a stronger humoral and cellular immune response over materials‐matched controls without the use of traditional adjuvants.
- Open Access
Intra-Lymph Node Crosslinking of Antigen-Bearing Polymers Enhances Humoral Immunity and Dendritic Cell Activation
Lymph node (LN)-resident dendritic cells (DCs) are a promising target for vaccination given their professional antigen-presenting capabilities and proximity to a high concentration of immune cells. Direct intra-LN injection has been shown to greatly enhance the immune response to vaccine antigens compared to traditional intramuscular injection but is infeasible to implement clinically. Employing the passive lymphatic flow of antigens to target LNs has been shown to increase total antigen uptake by DCs more than inflammatory adjuvants, which recruit peripheral DCs. Herein, we describe a novel vaccination platform in which two complementary multi-arm poly(ethylene glycol) (PEG) polymers—one covalently bound to the model antigen ovalbumin (OVA)—are injected subcutaneously into two distinct sites that drain to the same LN through different lymphatic vessels and, upon meeting in the LN, rapidly crosslink. This system improves OVA delivery to, and residence time within, the draining LN compared to all control groups, with the crosslinking of the two PEG components improving humoral immunity without the need for any pathogen-mimicking adjuvants. Further, we observed a significant increase in non-B/T lymphocytes in LNs cross-presenting the OVA peptide SIINFEKL on MHC I over a dose-matched control containing alum, the most common clinical adjuvant, as well as an increase in DC activation in the LN. These data suggest that this platform can be used to deliver antigens to LN-resident immune cells to produce a stronger humoral and cellular immune response over materials-matched controls without the use of traditional adjuvants. Translational Impact Statement Vaccines save millions of lives each year; however, they often require more than one injection to confer protection and do not always provide long-term immunity. Transitioning from intramuscular injections to intra-lymph node injections has been shown to greatly increase immunity conferred by vaccination but is infeasible to implement clinically. Herein, we present a biomaterial-based vaccination strategy that delivers antigen to the lymph nodes after a pair of remote injections, which increases the duration of immune cell exposure to the vaccine and, consequently, enhances humoral immunity.
Open AccessIntra-Lymph Node Crosslinking of Antigen-Bearing Polymers Enhances Humoral Immunity and Dendritic Cell Activation
Lymph node (LN)-resident dendritic cells (DCs) are a promising target for vaccination given their professional antigen-presenting capabilities and proximity to a high concentration of immune cells. Direct intra-LN injection has been shown to greatly enhance the immune response to vaccine antigens compared to traditional intramuscular injection but is infeasible to implement clinically. Employing the passive lymphatic flow of antigens to target LNs has been shown to increase total antigen uptake by DCs more than inflammatory adjuvants, which recruit peripheral DCs. Herein, we describe a novel vaccination platform in which two complementary multi-arm poly(ethylene glycol) (PEG) polymers—one covalently bound to the model antigen ovalbumin (OVA)—are injected subcutaneously into two distinct sites that drain to the same LN through different lymphatic vessels and, upon meeting in the LN, rapidly crosslink. This system improves OVA delivery to, and residence time within, the draining LN compared to all control groups, with the crosslinking of the two PEG components improving humoral immunity without the need for any pathogen-mimicking adjuvants. Further, we observed a significant increase in non-B/T lymphocytes in LNs cross-presenting the OVA peptide SIINFEKL on MHC I over a dose-matched control containing alum, the most common clinical adjuvant, as well as an increase in DC activation in the LN. These data suggest that this platform can be used to deliver antigens to LN-resident immune cells to produce a stronger humoral and cellular immune response over materials-matched controls without the use of traditional adjuvants. Translational Impact Statement Vaccines save millions of lives each year; however, they often require more than one injection to confer protection and do not always provide long-term immunity. Transitioning from intramuscular injections to intra-lymph node injections has been shown to greatly increase immunity conferred by vaccination but is infeasible to implement clinically. Herein, we present a biomaterial-based vaccination strategy that delivers antigen to the lymph nodes after a pair of remote injections, which increases the duration of immune cell exposure to the vaccine and, consequently, enhances humoral immunity.
- Open Access
A TLR7 Agonist Conjugated to a Nanofibrous Peptide Hydrogel as a Potent Vaccine Adjuvant
Toll-like receptors (TLRs) recognize pathogen- and damage-associated molecular patterns and, in turn, trigger the release of cytokines and other immunostimulatory molecules. As a result, TLR agonists are increasingly being investigated as vaccine adjuvants, though many of these agonists are small molecules that quickly diffuse away from the vaccination site, limiting their co-localization with antigens and, thus, their effect. Here, the small-molecule TLR7 agonist 1V209 is conjugated to a positively-charged multidomain peptide (MDP) hydrogel, K 2 , which was previously shown to act as an adjuvant promoting humoral immunity. Mixing the 1V209-conjugated K 2 50:50 with the unfunctionalized K 2 produces hydrogels that retain the shear-thinning and self-healing physical properties of the original MDP, while improving the solubility of 1V209 more than 200-fold compared to the unconjugated molecule. When co-delivered with ovalbumin as a model antigen, 1V209-functionalized K 2 produces antigen-specific IgG titers that were statistically similar to alum, the gold standard adjuvant, and a significantly lower ratio of Th2-associated IgG1 to Th1-associated IgG2a than alum, suggesting a more balanced Th1 and Th2 response. Together, these results suggest that K 2 MDP hydrogels functionalized with 1V209 are a promising adjuvant for vaccines against infectious diseases, especially those benefiting from a combined Th1 and Th2 immune response. Table of Contents: Activation of toll-like receptors (TLRs) stimulates a signaling cascade to induce an immune response. A TLR7 agonist was conjugated to an injectable peptide hydrogel, which was then used to deliver a model vaccine antigen. This platform produced antibody titers similar to the gold standard adjuvant alum and demonstrated an improved balance between Th1- and Th2-mediated immunity over alum.
Open AccessA TLR7 Agonist Conjugated to a Nanofibrous Peptide Hydrogel as a Potent Vaccine Adjuvant
Toll-like receptors (TLRs) recognize pathogen- and damage-associated molecular patterns and, in turn, trigger the release of cytokines and other immunostimulatory molecules. As a result, TLR agonists are increasingly being investigated as vaccine adjuvants, though many of these agonists are small molecules that quickly diffuse away from the vaccination site, limiting their co-localization with antigens and, thus, their effect. Here, the small-molecule TLR7 agonist 1V209 is conjugated to a positively-charged multidomain peptide (MDP) hydrogel, K 2 , which was previously shown to act as an adjuvant promoting humoral immunity. Mixing the 1V209-conjugated K 2 50:50 with the unfunctionalized K 2 produces hydrogels that retain the shear-thinning and self-healing physical properties of the original MDP, while improving the solubility of 1V209 more than 200-fold compared to the unconjugated molecule. When co-delivered with ovalbumin as a model antigen, 1V209-functionalized K 2 produces antigen-specific IgG titers that were statistically similar to alum, the gold standard adjuvant, and a significantly lower ratio of Th2-associated IgG1 to Th1-associated IgG2a than alum, suggesting a more balanced Th1 and Th2 response. Together, these results suggest that K 2 MDP hydrogels functionalized with 1V209 are a promising adjuvant for vaccines against infectious diseases, especially those benefiting from a combined Th1 and Th2 immune response. Table of Contents: Activation of toll-like receptors (TLRs) stimulates a signaling cascade to induce an immune response. A TLR7 agonist was conjugated to an injectable peptide hydrogel, which was then used to deliver a model vaccine antigen. This platform produced antibody titers similar to the gold standard adjuvant alum and demonstrated an improved balance between Th1- and Th2-mediated immunity over alum.
- 30 March 2023
- Published by Wiley in Advanced Materials
- Vol. 35 (22) , e2300228
A Scalable Platform for Fabricating Biodegradable Microparticles with Pulsatile Drug Release
Pulsatile drug delivery systems have the potential to improve patient adherence and therapeutic efficacy by providing a sequence of doses in a single injection. Herein, a novel platform, termed Particles Uniformly Liquified and Sealed to Encapsulate Drugs (PULSED) is developed, which enables the high‐throughput fabrication of microparticles exhibiting pulsatile release. In PULSED, biodegradable polymeric microstructures with an open cavity are formed using high‐resolution 3D printing and soft lithography, filled with drug, and sealed using a contactless heating step in which the polymer flows over the orifice to form a complete shell around a drug‐loaded core. Poly(lactic‐co‐glycolic acid) particles with this structure can rapidly release encapsulated material after delays of 10 ± 1, 15 ± 1, 17 ± 2, or 36 ± 1 days in vivo, depending on polymer molecular weight and end group. The system is even compatible with biologics, releasing over 90% of bevacizumab in its bioactive form after a two‐week delay in vitro. The PULSED system is highly versatile, offering compatibility with crystalline and amorphous polymers, easily injectable particle sizes, and compatibility with several newly developed drug loading methods. Together, these results suggest that PULSED is a promising platform for creating long‐acting drug formulations that improve patient outcomes due to its simplicity, low cost, and scalability.
- 30 March 2023
- Published by Wiley in Advanced Materials
- Vol. 35 (22) , e2300228
A Scalable Platform for Fabricating Biodegradable Microparticles with Pulsatile Drug Release
Pulsatile drug delivery systems have the potential to improve patient adherence and therapeutic efficacy by providing a sequence of doses in a single injection. Herein, a novel platform, termed Particles Uniformly Liquified and Sealed to Encapsulate Drugs (PULSED) is developed, which enables the high‐throughput fabrication of microparticles exhibiting pulsatile release. In PULSED, biodegradable polymeric microstructures with an open cavity are formed using high‐resolution 3D printing and soft lithography, filled with drug, and sealed using a contactless heating step in which the polymer flows over the orifice to form a complete shell around a drug‐loaded core. Poly(lactic‐co‐glycolic acid) particles with this structure can rapidly release encapsulated material after delays of 10 ± 1, 15 ± 1, 17 ± 2, or 36 ± 1 days in vivo, depending on polymer molecular weight and end group. The system is even compatible with biologics, releasing over 90% of bevacizumab in its bioactive form after a two‐week delay in vitro. The PULSED system is highly versatile, offering compatibility with crystalline and amorphous polymers, easily injectable particle sizes, and compatibility with several newly developed drug loading methods. Together, these results suggest that PULSED is a promising platform for creating long‐acting drug formulations that improve patient outcomes due to its simplicity, low cost, and scalability.
- Open Access
- 12 December 2022
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 119 (51)
Enhanced stability and clinical absorption of a form of encapsulated vitamin A for food fortification
Food fortification is an effective strategy to address vitamin A (VitA) deficiency, which is the leading cause of childhood blindness and drastically increases mortality from severe infections. However, VitA food fortification remains challenging due to significant degradation during storage and cooking. We utilized an FDA-approved, thermostable, and pH-responsive basic methacrylate copolymer (BMC) to encapsulate and stabilize VitA in microparticles (MPs). Encapsulation of VitA in VitA-BMC MPs greatly improved stability during simulated cooking conditions and long-term storage. VitA absorption was nine times greater from cooked MPs than from cooked free VitA in rats. In a randomized controlled cross-over study in healthy premenopausal women, VitA was readily released from MPs after consumption and had a similar absorption profile to free VitA. This VitA encapsulation technology will enable global food fortification strategies toward eliminating VitA deficiency.
- 12 December 2022
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 119 (51)
Open AccessEnhanced stability and clinical absorption of a form of encapsulated vitamin A for food fortification
Food fortification is an effective strategy to address vitamin A (VitA) deficiency, which is the leading cause of childhood blindness and drastically increases mortality from severe infections. However, VitA food fortification remains challenging due to significant degradation during storage and cooking. We utilized an FDA-approved, thermostable, and pH-responsive basic methacrylate copolymer (BMC) to encapsulate and stabilize VitA in microparticles (MPs). Encapsulation of VitA in VitA-BMC MPs greatly improved stability during simulated cooking conditions and long-term storage. VitA absorption was nine times greater from cooked MPs than from cooked free VitA in rats. In a randomized controlled cross-over study in healthy premenopausal women, VitA was readily released from MPs after consumption and had a similar absorption profile to free VitA. This VitA encapsulation technology will enable global food fortification strategies toward eliminating VitA deficiency.
- 16 November 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 14 (671) , eabo3445
Diet-derived metabolites and mucus link the gut microbiome to fever after cytotoxic cancer treatment
Not all patients with cancer and severe neutropenia develop fever, and the fecal microbiome may play a role. In a single-center study of patients undergoing hematopoietic cell transplant ( n = 119), the fecal microbiome was characterized at onset of severe neutropenia. A total of 63 patients (53%) developed a subsequent fever, and their fecal microbiome displayed increased relative abundances of Akkermansia muciniphila , a species of mucin-degrading bacteria ( P = 0.006, corrected for multiple comparisons). Two therapies that induce neutropenia, irradiation and melphalan, similarly expanded A. muciniphila and additionally thinned the colonic mucus layer in mice. Caloric restriction of unirradiated mice also expanded A. muciniphila and thinned the colonic mucus layer. Antibiotic treatment to eradicate A. muciniphila before caloric restriction preserved colonic mucus, whereas A. muciniphila reintroduction restored mucus thinning. Caloric restriction of unirradiated mice raised colonic luminal pH and reduced acetate, propionate, and butyrate. Culturing A. muciniphila in vitro with propionate reduced utilization of mucin as well as of fucose. Treating irradiated mice with an antibiotic targeting A. muciniphila or propionate preserved the mucus layer, suppressed translocation of flagellin, reduced inflammatory cytokines in the colon, and improved thermoregulation. These results suggest that diet, metabolites, and colonic mucus link the microbiome to neutropenic fever and may guide future microbiome-based preventive strategies.
- 16 November 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 14 (671) , eabo3445
Diet-derived metabolites and mucus link the gut microbiome to fever after cytotoxic cancer treatment
Not all patients with cancer and severe neutropenia develop fever, and the fecal microbiome may play a role. In a single-center study of patients undergoing hematopoietic cell transplant ( n = 119), the fecal microbiome was characterized at onset of severe neutropenia. A total of 63 patients (53%) developed a subsequent fever, and their fecal microbiome displayed increased relative abundances of Akkermansia muciniphila , a species of mucin-degrading bacteria ( P = 0.006, corrected for multiple comparisons). Two therapies that induce neutropenia, irradiation and melphalan, similarly expanded A. muciniphila and additionally thinned the colonic mucus layer in mice. Caloric restriction of unirradiated mice also expanded A. muciniphila and thinned the colonic mucus layer. Antibiotic treatment to eradicate A. muciniphila before caloric restriction preserved colonic mucus, whereas A. muciniphila reintroduction restored mucus thinning. Caloric restriction of unirradiated mice raised colonic luminal pH and reduced acetate, propionate, and butyrate. Culturing A. muciniphila in vitro with propionate reduced utilization of mucin as well as of fucose. Treating irradiated mice with an antibiotic targeting A. muciniphila or propionate preserved the mucus layer, suppressed translocation of flagellin, reduced inflammatory cytokines in the colon, and improved thermoregulation. These results suggest that diet, metabolites, and colonic mucus link the microbiome to neutropenic fever and may guide future microbiome-based preventive strategies.
- 12 August 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 12 (556)
Engineered PLGA microparticles for long-term, pulsatile release of STING agonist for cancer immunotherapy
Microfabricated particles mimic multiple intratumoral injections of STING agonist over weeks to improve ease of use and decrease metastasis.
- 12 August 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 12 (556)
Engineered PLGA microparticles for long-term, pulsatile release of STING agonist for cancer immunotherapy
Microfabricated particles mimic multiple intratumoral injections of STING agonist over weeks to improve ease of use and decrease metastasis.
- 18 December 2019
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 11 (523)
Biocompatible near-infrared quantum dots delivered to the skin by microneedle patches record vaccination
Near-infrared fluorescent microparticles administered to the skin via dissolvable microneedle patches can record vaccine delivery.
- 18 December 2019
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 11 (523)
Biocompatible near-infrared quantum dots delivered to the skin by microneedle patches record vaccination
Near-infrared fluorescent microparticles administered to the skin via dissolvable microneedle patches can record vaccine delivery.